Incidence Of Large B-cell Lymphoma Research Articles

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Introduction Anti-CD19 CAR-T has revolutionized the outcome of patients with refractory and/or relapsing large B-cell lymphoma. Anti-CD19 CAR-T significantly improved their median overall survival (Neelapu et al. NEJM 2017, Schuster et al. NEJM 2019, Abramson et al. Lancet 2020) and has defined a standard-of-care in third line therapy. Results have been reproduced in real-world settings (Iacoboni et al. Cancer Med 2021, Jacobson et al. Transplant Cell Ther 2022) and the clinical implementation of this therapy is expanding worldwide. Commercially approved anti-CD19 CAR-T cell therapies require patients to be treated in specialized (FACT accredited) medical centres and to stay near these centres for the first 28 days once these are administered. As CAR-T cell therapies for lymphoma are only offered in three academic centres across the province of Quebec despite its population of 9 million people and its enormous geographic footprint, we hypothesized that these limitations would result in a geographic disparity in the delivery of care. Our aim was to evaluate the access to this innovative therapy in the province of Quebec. Methods We retrieved the postal codes of all patients living in the province of Quebec who received commercial CAR-T from its launch in August 14th 2019 up until June 30th 2022. We grouped these patients according to their respective administrative regions, taking into account their relative population densities. No difference in the incidence of lymphoma in Quebec is reported across administrative regions. Results Quebec covers a large territory of 1 667 441 km2 divided in 17 administrative regions (figure 1). Maisonneuve-Rosemont Hospital was the first center to offer CAR-T cell therapy in Quebec and is located in the region of Montreal, followed by CHU de Québec - university Laval in the region of Capitale-Nationale and McGill University Health Centre also in Montreal. Between August 14th 2019 and June 30th 2022, 108 patients have been treated from 16 of the 17 administrative regions in Quebec. In 2019: 9 patients from 4 of the 17 administrative regions were treated, in 2020: 23 patients from 9 of the 17 regions were treated, in 2021: 47 patients from 12 of the 17 regions were treated and in the first semester of 2022: 29 patients from 13 of the 17 regions were treated. Table 1 depicts the administrative regions of the 108 patients of our cohort treated over our first 3 years of activity, the representation of each of these regions amongst our cohort and their share of the Quebec population. The administrative regions where the CAR-T centers are located (Montreal and Capitale-Nationale) contributed significantly to the number of patients infused, but the numbers are below expected based on the actual population. Following the opening of a second CAR-T cell unit in the Capitale-Nationale, patients from 3 new administrative regions were treated. Capitale-Nationale is located East of Montreal and the patients from these 3 new administrative regions (namely Bas-St-Laurent, Gaspésie-Îles-de-la-Madelaine and Nord-du-Québec) are further away from Montreal. Discussion Based on the incidence of large B-cell lymphoma in the province of Quebec and the outcomes following actual standard therapies, approximately 60 patients should be eligible for CAR-T in Quebec per year. Our results demonstrates that although CAR-T are available as standard-of-care in Quebec since August 2019, not all patients throughout the province have had access to this therapy probably because of many challenges patients face to obtain this potential beneficial therapy. Although the COVID-19 pandemic has been a significant impediment, we believe that competitive trials, reduced referrals due to strict eligibility criteria and patients' reluctance to travel away from their home represent significant limitations. In order to facilitate the implementation of an expected increasing number of indications for CAR-T, our data provide basis to survey patients and healthcare workers in Quebec to better understand the limitations to the implementation of this therapy in a geographically large region such as the province of Quebec. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years

IntroductionChimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and Drug Administration (FDA) approvals of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel). Although the incidence of LBCL is highest among patients age ≥ 65, clinical trials supporting approval of these 2 products primarily enrolled younger patients. Safety data for axi-cel and tis-cel in older patients is limited. MethodsIn this analysis, we queried the FDA Adverse Events Reporting System (FAERS) database for cases associated with axi-cel or tis-cel from the FDA approval dates for the LBCL indication for each product through December 31, 2019, and compared adverse events (AEs) reported for cases involving patients aged <65 and ≥ 65. ResultsA total of 804 cases were retrieved, with 333 (41%) involving patients age ≥ 65. Cytokine release syndrome (CRS) was the most common AE reported in both age groups. Cases involving older patients had a significantly higher proportion of neurological AEs, including CAR T-cell-related encephalopathy syndrome (8% vs. 4%, p = 0.03). Some individual clinical features of CRS were significantly more common among younger age group cases, including pyrexia (33% vs. 23%, p < 0.01), tachycardia (10% vs. 5%, p < 0.01), and thrombocytopenia (4% vs. 2%, p = 0.03). DiscussionIn this age-based analysis of FAERS reports for patients treated with axi-cel or tis-cel, we identified differences in patterns of AEs experienced. This large-scale post-marketing study complements clinical trial safety data and may help inform clinicians' decision making when treating adult patients with CAR-T cell therapy.